Haemonetics Corporation vs. ResMed Inc.
ResMed Inc. (RMD) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| HAE | RMD | |
|---|---|---|
| Market Cap | $4.68 billion | $31.89 billion |
| Revenue (TTM) | $1.35 billion | $5.65 billion |
| Net Income (TTM) | $96.29 million | $1.52 billion |
RMD leads on 3 of 3 size & scale factors.
Valuation
| HAE | RMD | |
|---|---|---|
| P/E Ratio | 49.68 | 21.13 |
| Price / Book | 5.59 | 4.84 |
| Price / Sales | 3.46 | 5.64 |
RMD leads on 2 of 3 valuation factors.
Profitability
| HAE | RMD | |
|---|---|---|
| Net Margin | 7.12% | 26.94% |
| Return on Equity | 11.50% | 23.13% |
RMD leads on 2 of 2 profitability factors.
Dividend
| HAE | RMD | |
|---|---|---|
| Dividend Yield | — | 1.20% |
| Payout Ratio | — | 25.31 |
HAE and RMD split the dividend factors evenly.
Risk & Sentiment
| HAE | RMD | |
|---|---|---|
| Short Interest | 1.81% | 4.04% |
HAE leads on 1 of 1 risk & sentiment factors.
Dig deeper: HAE overview, HAE financials, RMD overview, RMD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.